TY - JOUR
T1 - Biphasic modulation in the trigeminal nociceptive neuronal responses by the intracerebroventricular prostaglandin E2 may be mediated through different EP receptors subtypes in rats
AU - Oka, Takakazu
AU - Hori, Tetsuro
AU - Hosoi, Masako
AU - Oka, Kae
AU - Abe, Michie
AU - Kubo, Chiharu
N1 - Funding Information:
The following compounds were gifts which authors gratefully acknowledge: butaprost from Dr. P.J. Gardiner, Bayer, UK Ltd.; MB28767 from Ms. L. Webb, Rhone-Poulenc Rorer, Ltd., UK; SC19220 from Dr. R.A. Marks, Searle, USA. This work was supported in part by Grants-in-Aid for Scientific Research (09557006 and 08877017 to T.H., 09770040 to T.O.) and a Grant from the Naito Foundation (95-185 to T.O.). This experiment was reviewed by the Committee of Ethics on Animal Experiments at the Faculty of Medicine, Kyushu University and was carried out under the control of the Guidelines for Animal Experiments at the Faculty of Medicine, Kyushu University and the Law (No. 105) and Notification (No. 6) of the Government.
PY - 1997/10/17
Y1 - 1997/10/17
N2 - To determine which prostaglandin E2 (PGE2) receptor subtypes are involved in the brain-derived PGE2-induced changes in nociception, we injected synthetic EP1, EP2 and EP3 receptor agonists (0.01 fmol to 10 nmol) into the lateral cerebroventricle (LCV) of urethane-anesthetized rats and observed the changes in the responses of the wide dynamic range (WDR) neurons in the trigeminaI nucleus caudalis to noxious pinching of facial skin. The enhancement and suppression of the nociceptive responses of the WDR neurons were observed after the LCV injection of MB28767 (an EP3 receptor agonist) at a low dose range (1-100 fmol) and 17-phenyl-ω-trinor PGE2 (an EP1 receptor agonist) at high doses (1-10 nmol), respectively. Furthermore, the suppression of nociceptive neuronal responses after the LCV injection of PGE2 (1 nmol) was completely blocked by SC19220 (an EP1 receptor antagonist, 300 nmol). On the other hand, butaprost (an EP2 receptor agonist) at any doses tested (0.1 fmol to 1 nmol) had no effect on the nociceptive responses. The LCV injection of MB28767 (10 fmol) and 17-phenyl- ω-trinor PGE2 (1 nmol), which respectively enhanced and suppressed the nociceptive neuronal responses, did not affect the responses of the low threshold mechanoreceptive neurons to innocuous tactile stimuli. These results provide electrophysiological evidence that brain-derived PGE2 induces mechanical hyperalgesia and hypoalgesia through EP3 and EP1 raceptors, respectively, in the rat.
AB - To determine which prostaglandin E2 (PGE2) receptor subtypes are involved in the brain-derived PGE2-induced changes in nociception, we injected synthetic EP1, EP2 and EP3 receptor agonists (0.01 fmol to 10 nmol) into the lateral cerebroventricle (LCV) of urethane-anesthetized rats and observed the changes in the responses of the wide dynamic range (WDR) neurons in the trigeminaI nucleus caudalis to noxious pinching of facial skin. The enhancement and suppression of the nociceptive responses of the WDR neurons were observed after the LCV injection of MB28767 (an EP3 receptor agonist) at a low dose range (1-100 fmol) and 17-phenyl-ω-trinor PGE2 (an EP1 receptor agonist) at high doses (1-10 nmol), respectively. Furthermore, the suppression of nociceptive neuronal responses after the LCV injection of PGE2 (1 nmol) was completely blocked by SC19220 (an EP1 receptor antagonist, 300 nmol). On the other hand, butaprost (an EP2 receptor agonist) at any doses tested (0.1 fmol to 1 nmol) had no effect on the nociceptive responses. The LCV injection of MB28767 (10 fmol) and 17-phenyl- ω-trinor PGE2 (1 nmol), which respectively enhanced and suppressed the nociceptive neuronal responses, did not affect the responses of the low threshold mechanoreceptive neurons to innocuous tactile stimuli. These results provide electrophysiological evidence that brain-derived PGE2 induces mechanical hyperalgesia and hypoalgesia through EP3 and EP1 raceptors, respectively, in the rat.
UR - http://www.scopus.com/inward/record.url?scp=0030776101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030776101&partnerID=8YFLogxK
U2 - 10.1016/S0006-8993(97)00802-0
DO - 10.1016/S0006-8993(97)00802-0
M3 - Article
C2 - 9401748
AN - SCOPUS:0030776101
SN - 0006-8993
VL - 771
SP - 278
EP - 284
JO - Molecular Brain Research
JF - Molecular Brain Research
IS - 2
ER -